Pfizer celebrates a year of achievements in 2015 annual review

PfizerPfizer Inc. (NYSE: PFE) has released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, the scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improve patient health.

"Our purpose at Pfizer is to bring therapies to patients that significantly improve their lives," said Pfizer Chairman and Chief Executive Officer Ian C. Read. "Thanks to the more than 97,000 Pfizer colleagues around the world, we met our yearly commitments and continued to build the company's capabilities toward our goal to become the world's premier, innovative biopharmaceutical company by the end of this decade."

As a result of our research as well as innovative collaborations with our peers and research partners, we saw great scientific progress across multiple therapeutic areas in 2015.

  • We advanced 39 potential new therapies in our R&D pipeline, representing the strongest progress in Pfizer's history.
  • Our research efforts in oncology have resulted in a broad and deep portfolio of compounds, including five immuno-oncology assets in human studies that have the potential to address the urgent therapeutic needs of cancer patients.
  • We advanced our investigational vaccines pipeline to research some of the most deadly infectious diseases that affect people of all ages.

In 2015, Pfizer made great strides to help ensure patients around the world have access to the Pfizer medicines and vaccines that are approved and available. "Our very license to operate depends on ensuring the medicines we make to improve patient health and wellbeing are available to as many people as possible," commented Sally Susman, Executive Vice President, Corporate Affairs. "Patient assistance is not a program or catchphrase, it is a commitment."

  • In 2015, we significantly expanded the eligibility of our U.S. patient assistance program, Pfizer RxPathways®. The program helped more than 250,000 people access our medicines during the year.
  • We continued global health partnerships including the International Trachoma Initiative at The Task Force for Global Health, which seeks to eliminate the world's leading cause of preventable blindness and marked 2015 with the 500 millionth dose donation of antibiotic Zithromax® (azithromycin).
  • 2015 was the 5th year of our partnership with Gavi, the Vaccine Alliance, in which we have pledged 740M doses of pneumococcal vaccines to immunize children in GAVI countries through 2025.
  • To address family planning needs of women in the developing world, our collaboration with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) completed its first-full year, and was successful in helping broaden access to injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), to tens of thousands of women across several countries in Africa and Asia.

Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...